Assessment of non-small cell lung cancer viability and necrosis with three radiopharmaceuticals

Hellenic Journal of Nuclear Medicine

Volumn 11, Issue 1, 2008, Pages 16-20

  Sobic Saranovic, Dragana P ^a   Pavlovic, Smiljana ^a   Jovanovic, Dragana ^a   Nebojsa, Kozarevic ^a   Todorovic Tirnanic, Mila ^a   Subotic, Dragan ^a   Artiko, Vera ^a   Obradovic, Vladimir ^a  

^a CLINICAL CENTER OF SERBIA   (Serbia)

Author keywords

201Thallium; 99mTc HMFG1; 99mTc sestamibi; MoAb; Non small cell lung cancer

Indexed keywords

CONTRAST MEDIUM; METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M; MONOCLONAL ANTIBODY TC 99M; RADIOPHARMACEUTICAL AGENT; THALLIUM CHLORIDE TL 201;

ADULT; AGED; ARTICLE; BONE METASTASIS; BRAIN METASTASIS; CANCER DIAGNOSIS; CANCER STAGING; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DRUG ACCUMULATION; DRUG TARGETING; DRUG UPTAKE; FEMALE; HUMAN; IMAGE ANALYSIS; IMMUNOSCINTIGRAPHY; INTERMETHOD COMPARISON; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; PREDICTION; RADIATION DOSE; SENSITIVITY AND SPECIFICITY; SOFT TISSUE METASTASIS; THORAX RADIOGRAPHY; TREATMENT RESPONSE; TUMOR CLASSIFICATION; TUMOR DIFFERENTIATION; TUMOR NECROSIS; WHOLE BODY SCINTISCANNING;

AGED; CARCINOMA, NON-SMALL-CELL LUNG; CELL SURVIVAL; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NECROSIS; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TECHNETIUM; TECHNETIUM TC 99M SESTAMIBI; THALLIUM;

EID: 43249120176     PISSN: 11081430     EISSN: 17905427     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Chiti A, Schreiner FA, Crippa F et al. Nuclear medicine procedures in lung cancer. Eur J Nucl Med 1999; 26: 533-555.
2. Coleman E. PET in lung cancer. J Nucl Med 1999; 40: 814-820.
3. 18F fluorodeoxyglucose chest uptake in lung inflammation and infection. Clin Nucl Med 2000; 25: 273-276.
4. Ichiya Y, Kuwabara Y, Sasaki M et al. FDG-PET in infectious lesions: The detection and assessment of lesion activity. Ann Nucl Med 1996; 10: 185-191.
5. Abdel-Dayem HM, Scott A, Macapinlac H, Larson S. Tracer imaging in lung cancer. Eur J Nucl Med 1994; 21: 57-81.
6. Pauwels EKJ, McCready R, Stoot JHMB, Van Deurzen DFP. The mechanism of accumulation of tumour-localising radiopharmaceuticals. Eur J Nucl Med 1998; 25: 277-305.
7. Britton KE, Granowska M. Radioimmunoscintgiraphy in tumour identification. Cancer Surveys 1987; 6: 247-267.
8. 123I-labeled monoclonal antibody imaging in ovarian cancer. J Clin Oncol 1986; 4: 730-736.
9. Epenetos AA, Snook D, Durbin H et al. Limitations of radiolabelled monoclonal antibodies for localization of human neoplasm. Cancer Res 1986; 46: 3183-3191.
10. Nishiyama Y, Kawasaki Y, Yamamoto Y et al. Technetium-99m-MIBI and thallium-201 scintigraphy of primary lung cancer. J Nucl Med 1997: 38: 1358-1361.
11. 201Tl-chloride in primary lung cancer. Jpn J Nucl Med 1996; 33: 501-511.
12. Taylor-Papadimitriou J, Peterson JA, Arkilie J et al. Monoclonal antibodies to epithelium-specific components of the human milk fat globule membrane: production and reaction with cells in culture. Int J Cancer 1981; 28: 17-21.
13. Mather SJ, Elisson D. Reduction-mediated technetium-99m labeling of monoclonal antibodies. J Nucl Med 1990; 31: 692-697.
14. Glodenberg DM, Larson SM. Radioimmunodetection in cancer identification. J Nucl Med 1992; 33: 803-814.
15. 99mTc-tetrofosmin. Ann Nucl Med 2004; 18: 79-95.
16. 111In labelled HMFG1 F (ab′) 2 fragments. Cancer Res 1988; 48: 1977-1984.
17. 99mTc-Hexakis-2-Methoxy-Isobutylisonitrile in diagnosis and staging of lung cancer. Chest 2002; 122: 1361-1364.
18. 99mTc hexakis 2 methoxy isobutyl isonitrile in benign and malignant lesions in the lungs. Clin Nucl Med 1989; 14: 333-340.
19. 201Tl single photon emission computed tomography. Nucl Med Communicat 1993; 14: 602-610.
20. 201Tl SPECT in the differential diagnosis of solitary pulmonary nodules. Ann Nucl Med 2005; 19: 277-281.
21. 99mTc-MIBI lung imaging in the detection of lung cancer. Chinese J Nucl Med 1993; 13: 94-95.
22. Gany WI, Nguyen TQ, Benedetto MT et al. Use of early, late and SPECT thallium imaging in evaluating activity of soft tissue and bone tumors. J Nucl Med 1993; 34: 32P.
23. 99mTc-MIBI mammoscintigraphy of breast masses: early and delayed imaging. Nucl Med Commun 1995; 16: 150-156.
24. Pavlovic S, Sobic-Saranovic D, Jovanovic D et al. Evaluation of pulmonary diseases using thallium -201. Radiol Arch Srb (RAS) 1996; 5 (Suppl 1): 1001-1003.
25. 201Tl uptake in tumours. Eur J Nucl Med 1989; 15: 376-379.
26. Chiu ML, Kronauge JF, Piwnica-Worms D. Effect of mitochondrial and plasma membrane potentials on accumulation of hexakis (2-methoxy isobutyl isonitrile) Tc-99m cultured mouse fibroblast. J Nucl Med 1990; 31: 1646-1653.
27. Aktolun C, Bayhan H, Pabuccu Y et al. Assessment of tumour necrosis and detection of mediastinal lymph node metastasis in bronchial carcinoma with technetium-99m sestamibi imaging: comparison with CT. Eur J Nucl Med 1994; 21: 973-979.
28. 99mTc MIBI SPECT in prediction of prognosis in patients with small cell lung cancer. Ann Nucl Med 2006; 20: 269-275.
29. Cermik TF, Yuksel M, Karlikaya CK et al. Thallium-201 SPECT in advanced non-small cell lung cancer: in relation with chemotherapeutic response, survival distant metastasis and p53 status. Ann Nucl Med 2003; 17: 368-374.
30. 99mTc-sestamibi uptake by cerebellar metastasis from bronchogenic carcinoma. Clin Nucl Med 1993; 18: 887-890.
31. 99mTc-MIBI SPECT. Eur J Nucl Med 2001; 28: 799-806.
32. 99mTc sestamibi imaging in predicting clinical response to chemotherapy in lung cancer. Ann Nucl Med 2002; 16: 103-108.
33. Moretti JL, Hauet N, Caglar M et al. To use MIBI or not to use MIBI? That is the question when assessing tumour cells. Eur J Nucl Med Mol Imaging 2005; 32: 836-842.